Genetic characteristics of the Long QT Syndrome that appears with certain pharmacological treatments

Phase 1

• Conditions: Drug-induced Long QT Syndrome; Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

• Registration Number: EUCTR2018-000564-28-ES
• Lead Sponsor: Institut de Recerca H. de la Santa Creu i Sant Pau - IIB Sant Pau

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-03-13
• Last Update Posted: 18 June 2018

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Patients older than 18 years with a confirmed diagnosis of drug-induceded long QT syndrome who want to participate in the study and sign the informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 120
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-Patients under 18 years old
-Patients of non-Caucasian ethnicity
-Patients with a family history of congenital long QT syndrome
-Patients with complete left bundle branch block, stimulated rhythms or non-sinus rhythms not related to SQTL
-Patients with electrolyte abnormalities
-Patients who do not sign informed consent

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified